Overview of the findings from the European SOHO study

References

• Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr. Bull.19(2), 287–302 (1993).
   PubMed Web of Science ®Google Scholar
• Barnes TRE, Edwards JG. The side-effects of antipsychotic drugs, I: neuropsychiatric effects. In: Antipsychotic Drugs and Their Side-Effects. Barnes TRE (Ed.). Academic Press, London, UK, 213–247 (1993).
   Google Scholar
• Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ321, 1371–1376 (2000).
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry60, 553–564 (2003).
   PubMed Web of Science ®Google Scholar
• Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr. Res.43, 135–145 (2000).
   PubMed Web of Science ®Google Scholar
• Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet361(9369), 1581–1589 (2003).
   PubMed Web of Science ®Google Scholar
• Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs64(7), 701–723 (2004).
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB et al.; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry161(2 Suppl.), 1–56 (2004).
   PubMed Web of Science ®Google Scholar
• Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. Mosby, St Louis, MO, USA (1996).
   Google Scholar
• Hofer A, Hummer M, Huber R, Kurz M, Walch T, Fleischhacker WW. Selection bias in clinical trials with antipsychotics. J. Clin. Psychopharmacol.20(6), 699–702 (2000).
   PubMed Web of Science ®Google Scholar
• Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann. Intern. Med.127(8 Pt 2), 757–763 (1997).
   PubMed Web of Science ®Google Scholar
• Ho BC, Miller D, Nopoulos P, Andreasen NC. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J. Clin. Psychiatry60, 658–663 (1999).
   PubMed Web of Science ®Google Scholar
• Coley KC, Carter CS, Dapos SV, Maxwell R, Wilson JW, Branch RA. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. J. Clin. Psychiatry60, 850–856 (1999).
   PubMed Web of Science ®Google Scholar
• Dossenbach M, Erol A, el Mahfoud Kessaci M et al.; IC-SOHO Study Group. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine,quetiapine, risperidone, and haloperidol. J. Clin. Psychiatry65(3), 312–321 (2004).
   PubMed Web of Science ®Google Scholar
• Guy W. Clinical global impression. In: ECDEU Assessment Manual for Psychopharmacology, Revised. National Institute of Mental Health, MD, USA, 218–222 (1976).
   Google Scholar
• Haro JM, Kamath SA, Ochoa S et al.; SOHO Study Group. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr. Scand. Suppl.107(416), 16–23 (2003).
   Google Scholar
• Williams A. EuroQoL – a new facility for the measurement of health-related quality of life. Health Policy16, 199–208 (1990).
   PubMed Web of Science ®Google Scholar
• Haro JM, Edgell ET, Jones PB et al.; SOHO Study Group. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr. Scand.107(3), 222–232 (2003).
   PubMed Web of Science ®Google Scholar
• Haro JM, Edgell ET, Novick D et al.; SOHO advisory board. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr. Scand.111(3), 220–231 (2005).
   PubMed Web of Science ®Google Scholar
• Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D; SOHO Study Group. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur. Neuropsychopharmacol.17(4), 235–244 (2007).
   PubMed Web of Science ®Google Scholar
• Haro JM, Novick D, Suarez D, Alonso J, Lépine JP, Ratcliffe M; SOHO Study Group. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J. Clin. Psychopharmacol.26(6), 571–578 (2006).
   PubMed Web of Science ®Google Scholar
• Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr. Bull.29(1), 33–43 (2003).
   PubMedGoogle Scholar
• Lieberman JA, Stroup TS, McEvoy JP et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med.353(12), 1209–1223 (2005).
   PubMed Web of Science ®Google Scholar
• Covell NH, Jackson CT, Evans AC, Essock SM. Antipsychotic prescribing practices in Connecticut’s Public Mental Health System: rates of changing medications and prescribing styles. Schizophr. Bull.28, 17–29 (2002).
   PubMed Web of Science ®Google Scholar
• Williams CL, Johnstone BM, Kesterson JG, Javor KA, Schmetzer AD. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med. Care37, AS81–AS86 (1999).
   PubMed Web of Science ®Google Scholar
• Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology (Berl.)155, 230–233 (2001).
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Stroup TS et al.; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry163(4), 600–610 (2006).
   PubMed Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H et al.; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet371(9618), 1085–1097 (2008).
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Walhbeck K, Lönnqvist J et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ333(7561), 224 (2006).
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry162, 441–449 (2005).
   PubMed Web of Science ®Google Scholar
• Haro JM, Ochoa S, Gervin M, Mavreas V, Jones P. Assessment of remission in schizophrenia with the CGI and CGI-SCH scales. Acta Psychiatr. Scand.115(2), 163–164 (2007).
   PubMedGoogle Scholar
• Suarez D, Haro JM, Novick D, Ochoa S. Marginal structural models might overcome confounding when analyzing multiple treatment effects in observational studies. J. Clin. Epidemiol.61(6), 525–530 (2008).
   PubMed Web of Science ®Google Scholar
• Jones PB, Barnes TR, Davies L et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry63(10), 1079–1087 (2006).
   PubMed Web of Science ®Google Scholar
• Robinson DG, Woerner MG, McMeniman M et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry161, 473–479 (2004).
   PubMed Web of Science ®Google Scholar
• Lambert M, Haro JM, Novick D et al. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr. Scand.111(3), 232–243 (2005).
   PubMed Web of Science ®Google Scholar
• Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinol.28, 83–96 (2003).
   PubMed Web of Science ®Google Scholar
• Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res.35, 51–68 (1999).
   PubMed Web of Science ®Google Scholar
• Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs16, 23–45 (2002).
   PubMed Web of Science ®Google Scholar
• Novick D, Bousono M, Suarez D et al.; SOHO Advisory Board. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study. Prog. Neuropsychopharmacol. Biol. Psychiatry29(6), 972–982 (2005).
   PubMed Web of Science ®Google Scholar
• Parepally H, Chakravorty S, Levine J et al. The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents: a naturalistic study at a state psychiatric hospital. Prog. Neuropsychopharmacol. Biol. Psychiatry26(3), 437–440 (2002).
   PubMedGoogle Scholar
• Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr. Serv.54(5), 719–723 (2003).
   PubMed Web of Science ®Google Scholar
• Gasquet I, Haro JM, Novick D et al.; SOHO Study Group. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int. Clin. Psychopharmacol.20(4), 199–205 (2005).
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Suarez D, Lambert M, Lépine JP, Naber D. Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. Psychopharmacology (Berl.)191(4), 1015–1022 (2007).
   PubMedGoogle Scholar
• Usall J, Suarez D, Haro JM; the SOHO Study Group. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res.153(3), 225–231 (2007).
   PubMed Web of Science ®Google Scholar
• Curran MP, Perry CM. Spotlight on amisulpride in schizophrenia. CNS Drugs16(3), 207–211 (2002).
   PubMedGoogle Scholar
• Cutler AJ, Goldstein JM, Tumas JA. Dosing and switching strategies for quetiapine fumarate. Clin. Ther.24, 209–222 (2002).
   PubMed Web of Science ®Google Scholar
• Sparshatt A, Jones S, Taylor D. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs22(1), 49–68; discussion 69–72 (2008).
   PubMedGoogle Scholar
• Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N. Engl. J. Med.342(25), 1878–1886 (2000).
   PubMed Web of Science ®Google Scholar
• Haro JM, Kontodimas S, Negrin MA, Ratcliffe M, Suarez D, Windmeijer F. Methodological aspects in the assessment of treatment effects in observational health outcomes studies. Appl. Health Econ. Health Policy5(1), 11–25 (2006).
   PubMedGoogle Scholar